A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder.

Trial Profile

A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2013

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Duramed Pharmaceuticals Inc
  • Most Recent Events

    • 18 May 2012 Results published in the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 21 Jul 2009 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 26 Oct 2007 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top